SkinPro sells an unapproved, misbranded hydroquinone skin-bleaching drug without FDA approval.
What happened
FDA cited claims from the product label and website for SKINPRO ULTRA BRIGHTENER HYDROQUINONE, a skin bleaching/lightening drug available for purchase online. The label stated maximum strength hydroquinone and the website stated it works fast to eradicate dark spots. FDA said the product is an unapproved new drug and misbranded because no required FDA approval is in effect and it does not meet the rules for nonprescription drugs.
What FDA found
SkinPro distributes a skin-bleaching drug without an FDA-approved new drug application.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug subject to section 505G but lacks an approved application and does not meet section 505G requirements.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)FDA treats hydroquinone skin-bleaching products as new drugs because they were proposed not to be generally recognized as safe and effective.
section 201(p)(1) and section 505G(a)(4) of the FD&C Act, 21 U.S.C. 321(p)(1), 355h(a)(4)Introducing the unapproved and misbranded drug into interstate commerce is prohibited.
sections 301(a) and 301(d) of the FD&C Act, 21 U.S.C. 331(a), 331(d)
What FDA wants
FDA asks SkinPro to respond in writing within 15 working days, describe what it has done to correct the violations and prevent recurrence, and if complete correction is not possible, give reasons and a completion schedule.
Who should pay attention
- retailers and online marketplaces that sell skin-lightening creams
- brands that market hydroquinone skin-bleaching products
- companies that rely on website and label claims for OTC drug products
This is a summary. Read the original letter on fda.gov.